Black Rock Inc. Eliem Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 381,723 shares of ELYM stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

381,723

Previous 30,440 1154.02%

Holding current value

$1.57 Million

Previous $83,000 3169.88%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.6 - $10.2 $913,335 - $3.58 Million	351,283 Added 1154.02%	381,723 $2.71 Million
Q1 2024 May 10, 2024	SELL	$2.54 - $2.98 $1,790 - $2,100	-705 Reduced 2.26%	30,440 $83,000
Q4 2023 Feb 13, 2024	SELL	$2.45 - $2.85 $406 - $473	-166 Reduced 0.53%	31,145 $84,000
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.15 $1,440 - $1,830	-581 Reduced 1.82%	31,311 $82,000
Q2 2023 Aug 11, 2023	SELL	$2.34 - $3.72 $1,893 - $3,009	-809 Reduced 2.47%	31,892 $89,000
Q1 2023 May 12, 2023	BUY	$2.3 - $4.64 $1,145 - $2,310	498 Added 1.55%	32,701 $94,000
Q4 2022 Feb 13, 2023	BUY	$2.48 - $3.69 $823 - $1,225	332 Added 1.04%	32,203 $118,000
Q3 2022 Nov 14, 2022	SELL	$2.72 - $3.97 $1,128 - $1,647	-415 Reduced 1.29%	31,871 $102,000
Q2 2022 Aug 12, 2022	SELL	$2.77 - $8.4 $850,553 - $2.58 Million	-307,059 Reduced 90.49%	32,286 $97,000
Q1 2022 May 12, 2022	SELL	$8.01 - $13.15 $136,962 - $224,851	-17,099 Reduced 4.8%	339,345 $2.85 Million
Q4 2021 Feb 10, 2022	BUY	$8.61 - $20.47 $209,377 - $497,789	24,318 Added 7.32%	356,444 $3.73 Million
Q3 2021 Nov 09, 2021	BUY	$14.45 - $28.61 $4.8 Million - $9.5 Million	332,126 New	332,126 $5.97 Million

Others Institutions Holding ELYM

# of Institutions

Shares Held

53.1M

Call Options Held

Put Options Held

View Full List

About Eliem Therapeutics, Inc.

Ticker ELYM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,567,700
Market Cap $109M
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...

More about ELYM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account